Related Experiment Videos

Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance

Maciej Banach1, Malgorzata Malodobra-Mazur, Anna Gluba

  • 1Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland. maciejbanach@aol.co.uk

Current Pharmaceutical Design
|January 3, 2013
PubMed

Insights

Statins can improve cardiovascular health but may increase the risk of new-onset diabetes (NOD). Research is needed to clarify this risk in different populations and guide appropriate statin therapy.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Statins are widely used for managing plasma lipid profiles and preventing vascular events.
  • Statin therapy is linked to potential side effects, including disruption of insulin signaling pathways.
  • This disruption may impact insulin sensitivity, pancreatic beta-cell function, and adipokine secretion.

Purpose of the Study:

  • To investigate the association between statin use and the risk of new-onset diabetes (NOD).
  • To determine if the risk of NOD is a dose-dependent class effect of statins.
  • To identify specific individual groups at higher risk for statin-associated NOD.

Main Methods:

  • Review of existing data on statin use and its effects on metabolic pathways.
  • Analysis of the dose-dependency of the statin-NOD association.
  • Evaluation of the balance between cardiovascular benefits and diabetes risk.

Main Results:

  • Statin-associated risk of NOD appears to be a dose-dependent class effect.
  • Cardiovascular benefits of statins in high-risk individuals generally outweigh the risks.
  • The role of statins in primary prevention for low-risk individuals remains under investigation.

Conclusions:

  • Further randomized, placebo-controlled trials are necessary to definitively assess the risk of NOD with statin therapy.
  • Careful patient selection and NOD as a primary endpoint are crucial for future research.
  • The decision to initiate statin therapy should weigh cardiovascular benefits against potential metabolic risks, particularly in specific patient populations.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...